Sacrosidase is an enzyme replacement therapy used for the treatment of congenital sucrase-isomaltase deficiency (CSID). People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and children.
- Mechanism
- Curator reviewed
Sacrosidase is a [beta]-fructofuranoside fructohydrolase that hydrolyzes sucrose. Unlike human intestinal sucrase-isomaltase, it has no activity with oligosaccharides containing 1,6 glucosyl bonds.
- Primary indication
- For the treatment of congenital sucrose-isomaltase deficiency (CSID).Curator reviewed · 1 structured indication
- First approval
- United States, 1998
- Brand names
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with Sacrosidase, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account